Group 1 - Knightscope, Inc. (KSCP) closed at $6.06, with a 25.7% gain over the past four weeks, and a mean price target of $17 suggests an upside potential of 180.5% [1] - The mean estimate includes three short-term price targets with a standard deviation of $11.36, indicating variability; the lowest estimate of $9 suggests a 48.5% increase, while the highest estimate of $30 indicates a potential surge of 395.1% [2] - Analysts show strong agreement on KSCP's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 5.3% over the past month, with one estimate rising and no negative revisions [12] - KSCP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [10][13]

Core Viewpoint - FTAI Aviation (FTAI) has shown a significant price increase of 14.2% over the past four weeks, with analysts projecting a mean price target of $171, indicating a potential upside of 38.6% from the current price of $123.35 [1] Price Targets and Analyst Consensus - The average price target for FTAI includes 12 short-term estimates ranging from a low of $123 to a high of $300, with a standard deviation of $46.90, suggesting variability in analyst predictions [2] - The lowest estimate indicates a slight decline of 0.3%, while the highest estimate suggests a substantial upside of 143.2% [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding FTAI's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 1.7% over the past month, with one estimate rising and no negative revisions [12] - FTAI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13]

Core Viewpoint - Rambus (RMBS) has shown a significant price increase of 12.2% over the past four weeks, with a mean price target of $72.25 indicating a potential upside of 28.3% from the current price of $56.30 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $9.97, where the lowest estimate is $55 (indicating a 2.3% decline) and the highest estimate is $90 (indicating a 59.9% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about RMBS's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 2% increase in the Zacks Consensus Estimate over the past month [11][12] - RMBS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead, as empirical research indicates that they rarely predict actual stock price movements accurately [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Zymeworks Inc. (ZYME) shows potential for significant upside, with a mean price target of $21.35 indicating a 76.7% increase from its current price of $12.08 [1] Price Targets and Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $7.45, indicating variability among analysts [2] - The lowest estimate is $12, suggesting a slight decline of 0.7%, while the highest estimate predicts a surge of 148.3% to $30 [2] - Analysts' price targets are often questioned for their reliability, as they may mislead investors rather than provide accurate guidance [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about ZYME's earnings, with a consensus indicating better-than-previously estimated earnings [4] - The Zacks Consensus Estimate for the current year has risen by 6.2% over the past month, with four estimates increasing and no negative revisions [12] - A strong correlation exists between earnings estimate revisions and near-term stock price movements, suggesting potential upside for ZYME [11] Zacks Rank and Investment Potential - ZYME holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [13]

Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) closed the last trading session at $13.36, gaining 11.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.90 indicates a 138.8% upside potential.The average comprises 10 short-term price targets ranging from a low of $27 to a high of $38, with a standard deviation of $4.01. While the lowest estimate indicates an increase of 102.1 ...

Core Viewpoint - Spire Global, Inc. (SPIR) has seen a 7.2% increase in share price over the past four weeks, closing at $10.38, with analysts suggesting a potential upside of 59.9% based on a mean price target of $16.60 [1] Price Targets - The average price target consists of five estimates ranging from a low of $13 to a high of $20, with a standard deviation of $2.51, indicating variability among analysts [2] - The lowest estimate suggests a 25.2% increase from the current price, while the highest estimate indicates a potential upside of 92.7% [2] Analyst Sentiment - Analysts are optimistic about SPIR's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 8.2%, with one estimate moving higher and no negative revisions [12] Zacks Rank - SPIR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside [13]

Core Viewpoint - Kamada (KMDA) shows significant upside potential with a mean price target of $14.17, indicating a 106.9% increase from the current price of $6.85 [1] Price Targets and Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $3.13, suggesting variability among analysts [2] - The lowest estimate of $11 indicates a 60.6% increase, while the highest estimate suggests a 192% surge to $20 [2] - A low standard deviation indicates a high degree of agreement among analysts regarding price movement [9] Analyst Sentiment and Earnings Estimates - Analysts are increasingly optimistic about KMDA's earnings prospects, as reflected in higher EPS estimates [11] - The Zacks Consensus Estimate for the current year has risen by 11% over the past month, with two estimates increasing and no negative revisions [12] - KMDA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Price targets should not be the sole basis for investment decisions, as they can mislead investors [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Shares of Candel Therapeutics, Inc. (CADL) have gained 3.2% over the past four weeks to close the last trading session at $5.45, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21 indicates a potential upside of 285.3%.The average comprises four short-term price targets ranging from a low of $15 to a high of $25, with a standard deviation of $4.90. While the lowest estimate ind ...

Pagaya Technologies Ltd. (PGY) closed the last trading session at $17.13, gaining 50.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $22.03 indicates a 28.6% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $6.97. While the lowest estimate of $13.75 indicates a 19.7% decline from the current price level, the most optimistic ...

Group 1 - Janus International Group, Inc. (JBI) shares have increased by 18.5% over the past four weeks, closing at $8.25, with a mean price target of $10.90 indicating a potential upside of 32.1% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $2.97, where the lowest estimate is $7.50 (indicating a 9.1% decline) and the highest estimate is $14 (indicating a 69.7% increase) [2] - Analysts have shown strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 35.4% over the last 30 days [11][12] Group 2 - JBI currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The consensus price target, while not entirely reliable, suggests a positive direction for JBI's stock price movement [13] - Analysts' price targets can often be overly optimistic due to business incentives, which may lead to inflated estimates [8]